Innovent Biologics Inc., a leading biopharmaceutical company, released its 2024 Annual Report, highlighting significant business updates and financial performance. The company reported a 51.8% increase in revenue, reaching RMB 9,421,888,000, and a gross profit of RMB 7,911,678,000, marking a 56.1% rise compared to the previous year. Innovent achieved profitability with a loss reduction of 90.8% year-over-year, posting a loss of RMB 94,631,000 for the year. Notably, the company recorded a Non-IFRS profit of RMB 331,611,000, a turnaround from the previous year's loss. The year 2024 marked historic milestones for Innovent, with record-high revenue and an expanded product portfolio of 15 approved products. The full report can be accessed through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。